TouchIMMUNOLOGY got the opportunity to catch up with Prof. Ronald Van Vollenhoven (Amsterdam UMC, Amsterdam, the Netherlands) to discuss the final recommendations from the DORIS taskforce in defining remission in systemic lupus erythematosus.
The abstract ‘The 2021 DORIS Definition Of Remission In SLE – Final Recommendations from an International Task Force.‘ (OP0296), was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.
- Why has there been a lack of consensus over the definition of remission in systemic lupus erythematosus (SLE)? (0:14)
- What have been the limitations of the potential definitions of remission? (1:07)
- Could you tell us a little about the DORIS Taskforce, its members and objectives? (3:01)
Disclosures: Ronald Van Vollenhoven discloses receiving research support (institutional grants): BMS, GSK, Lilly, UCB; support for educational programs (institutional grants): Pfizer, Roche; consultancy, for which institutional and/or personal honoraria were received: AbbVie, AstraZeneca, Biogen, Biotest, Celgene, Galapagos, Gilead, Janssen, Pfizer, Servier, UCB; speaker, for which institutional and/or personal honoraria were received: AbbVie, Galapagos, Janssen, Pfizer UCB.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
Share this Video
Related Videos In Systemic Lupus Erythematosus
Kevin Winthrop, ACR 2022: Anifrolumab for systemic lupus erythematosus – safety findings from the 3-year TULIP extension study
TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) were phase 3, randomized, double-blind, placebo-controlled trials that investigated the efficacy and safety of anifrolumab, a fully human IgG1 κ monoclonal antibody, in the treatment of systemic lupus erythematosus. In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to learn more about […]
Victoria P. Werth, ACR 2022: Findings from the phase 2 LILAC study of BIIB059 in cutaneous lupus erythematosus
Part B of the phase 2 LILAC study (NCT02847598) investigated BIIB059, a humanized monoclonal antibody against BDCA2, for the treatment of cutaneous lupus erythematosus (CLE). In this touchIMMUNOLOGY interview, we were delighted to speak with Prof. Victoria P. Werth (University of Pennsylvania, Philadelphia, PA, USA) around the unmet needs in the treatment of CLE, the […]
Jorge Sanchez-Guerrero, ACR 2022: Belimumab for mucocutaneous manifestations of systemic lupus erythematosus – findings from a pooled post hoc analysis
Mucocutaneous manifestations affect over 80% of patients with systemic lupus erythematosus (SLE) and can significantly impact on patient quality of life. touchIMMUNOLOGY were delighted to speak with Prof. Jorge Sanchez-Guerrero (University of Toronto, Toronto, ON, Canada) around his post hoc analysis investigating the effects of belimumab on the mucocutaneous manifestations of SLE. This information is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!